Janet E. Brown, BMedSci, MB BS, MSc, MD, FRCP, The University of Sheffield, Sheffield, UK, discusses the PRISM trial which looked at changing the schedule of the combination immunotherapy regimen of nivolumab and ipilimumab for renal cell carcinoma (RCC). In the experimental arm, ipilimumab was given every 12 weeks instead of every 3 weeks, alongside nivolumab. Patients in the experimental arm experienced significantly fewer grade 3 or grade 4 treatment-related adverse events than patients receiving ipilimumab every 3 weeks. There was no significant difference in objective response rate (ORR) or progression free survival (PFS) between the two patient populations. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.